- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02590796
Validating Studies to Assess the Diagnostic Accuracy of a Software Application for Detection and Monitoring of Attentional Deficits in Delirium
MICA: Development of a Software Application for Detection and Monitoring of Attentional Deficits in Delirium
The study has two phases: Phase B and Phase C. The purpose of the Phase B study is to determine the performance (sensitivity and specificity) of a smartphone application (DelApp) to identify delirium in the whole inpatient sample. The study also aims to determine the performance (sensitivity and specificity) of the DelApp to discriminate between delirium (with or without dementia) and dementia (without delirium).
The purpose of the Phase C study is to determine the efficacy of the DelApp software application in detecting delirium in unselected patients in an inpatient sample and to determine the performance of the DelApp to discriminate between delirium and dementia. The study also aims to explore the performance of the DelApp in tracking change in cognitive function.
Study Overview
Status
Intervention / Treatment
Detailed Description
The investigators previously developed a new neuropsychological test for the objective measurement of inattention in delirium, which was implemented on a purpose-built computerised device (Delbox). A prototype software application (DelApp) for smartphones has now been developed based on the same test.
The DelApp has many advantages over existing tests, including objectivity, automated scoring and ease-of-use. Studies in 30 hospital patients showed highly comparable performance between the Delbox and DelApp. Further proof-of-principle single-rater studies using the DelApp in more than 200 hospital patients have provided additional evidence of good performance of the DelApp.
Though there are strong positive findings from investigator pilot studies, larger-scale formal studies with blinded raters and more representative patient samples are now required.
The proposed study is part of a larger programme of work funded by the Medical Research Council (grant value £1.01M) on the optimisation and clinical validation of the DelApp, which consists of three stages: Phase A - optimisation of the DelApp and feasibility testing (REC no 15/SC00/19); Phase B - case-control studies in selected patients; and Phase C - validation studies in unselected patients. Ultimately investigators aim to generate a software product which will be fully licensed and commercially available to healthcare organisations.
The proposed Phase B studies will be carried out in hospitalised patients in general and acute medical wards and ICU. The objectives of these studies are (a) to assess diagnostic performance of the DelApp in discrete patient groups and to inform optimal cut-points (Phase B); and (b) to evaluate the diagnostic performance of the DelApp in unselected patients (Phase C). The studies will also contribute to a better understanding of the nature of neuropsychological deficits underlying delirium. At the end of these studies, the DelApp may be modified depending on the study results. Investigators will select the stimuli and subtests that provide the best balance of sensitivity and specificity.
Two case-control studies will be conducted involving patients recruited from general and acute wards (Study B.1) and ICU (Study B.2). Each study will run in two sites, i.e. the Royal Infirmary of Edinburgh (RIE) and the Glasgow Royal Infirmary (GRI). The performance of the DelApp (index test) against reference standard diagnosis will be independently assessed by two trained raters, with one pair of raters on each site. As in our prior case-control studies, convenience samples will be used, where clinicians are asked to identify patients in the target groups.
Hospitalised patients will be asked to undertake a number of tests at their bedside. These tests will be administered to patients once only. Patients will be visited by two different researchers on the same day, with a gap of approximately 15-60 min between assessment visits assuming that consent is provided in the first visit. The first visit will involve assessment of capacity and (in those thought likely to be capable of giving consent) obtaining informed consent, as well as assessment of delirium (reference tests) and cognition. The second visit will involve the DelApp assessment (index test). Thus, the index test and reference tests are administered by independent raters. Where the patient is unable to provide consent for themselves, proxy consent will be sought, and if granted, the same visits as above will occur.
The Phase C formal validation studies have a similar design to the case-control studies. The main difference is that unselected samples of patients will be recruited from general and acute medical wards (Study C.1) and ICU (Study C.2) in the GRI and RIE.
A subset of patients in studies C.1 and C.2 (N=60 combined) will undergo up to 4 repeat assessments (at least one day apart), along with the reference standard, to explore the performance of the DelApp in tracking change in cognitive function.
In the longitudinal assessments, researchers will ask patients able to provide consent at the time of recruitment if they consent to subsequent assessments even if at the time of these subsequent assessments the patient lacks capacity. However, during the subsequent assessments, it will be carefully checked if the patient assents to continue their participation in the study. In patients who initially lack capacity and have been included through consent from a legal proxy, and who are undergoing serial assessments, researchers will seek informed consent from patients at the beginning of each new testing session. If the patient regains capacity after the final assessment, the investigators will seek retrospective consent from the patient where possible.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Edinburgh, United Kingdom, EH16 4SA
- University of Edinburgh
-
Glasgow, United Kingdom, G4 0SF
- University of Glasgow
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Royal Infirmary of Edinburgh (RIE) and Glasgow Royal Infirmary (GRI) general wards and intensive care units.
Scottish Dementia Research Network Register and Psychology, Philosophy and Language Science (PPLS) volunteer database.
Description
Inclusion Criteria:
General Wards
- Aged 65 or over
- Capacity to provide written, informed consent or the availability of a suitable relative or welfare guardian/attorney who is able to provide informed consent on behalf of the participant.
ICU
- Aged 18 or over
- Capacity to provide written, informed consent or the availability of a suitable relative or welfare guardian/attorney who is able to provide informed consent on behalf of the patient.
Exclusion Criteria:
General Wards
- Unable to understand spoken task instructions
- Vision or hearing impairment severe enough to preclude testing or interview
- Photosensitive epilepsy
ICU
- Unable to understand spoken task instructions
- Pre-existing, known cognitive impairment including dementia
- Vision or hearing impairment severe enough to preclude testing or interview
- Photosensitive epilepsy
- A score on the Richmond Agitation-Sedation Scale of below -3
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Hospitalised patients with delirium
hospitalised patients with delirium in general wards.
|
This is an observational study.
Participants will receive no intervention.
|
Hospitalised patients with dementia/ no delirium
Hospitalised patients with a diagnosis of dementia who do not have delirium in general wards.
|
This is an observational study.
Participants will receive no intervention.
|
Hospitalised patients with no delirium or dementia
Hospitalised patients with no delirium or dementia in general wards.
|
This is an observational study.
Participants will receive no intervention.
|
Outpatients with dementia
People with a diagnosis of dementia who are living in the community.
|
This is an observational study.
Participants will receive no intervention.
|
Healthy volunteers
Healthy volunteers who are living in the community who do not have a cognitive impairment.
|
This is an observational study.
Participants will receive no intervention.
|
ICU delirium
Patients with delirium who are hospitalised in the intensive care units.
|
This is an observational study.
Participants will receive no intervention.
|
ICU no delirium
Patients who do not have delirium who are hospitalised in intensive care units.
|
This is an observational study.
Participants will receive no intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic accuracy of the DelApp for diagnosing delirium
Time Frame: Baseline
|
DelApp score against delirium diagnosed using DSM-5 criteria in the whole inpatient sample.
|
Baseline
|
Diagnostic accuracy of the DelApp to discriminate between delirium (with or without dementia) and dementia (without delirium).
Time Frame: Baseline
|
DelApp score against delirium diagnosed using DSM-5 criteria in groups with dementia and delirium.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Accuracy of DelApp in measuring delirium severity
Time Frame: Baseline
|
DelApp score against score on Delirium Rating Scale revised 98 (DRS-R98).
|
Baseline
|
Length of stay
Time Frame: up to 3 months
|
length of stay in hospital
|
up to 3 months
|
Mortality
Time Frame: 3 months
|
Mortality at three months post assessment
|
3 months
|
Discharge location
Time Frame: up to 3 months
|
Where patient is discharged to after hospital.
e.g home, care home.
|
up to 3 months
|
Accuracy of DelApp to measure within-subject change in attentional functioning and delirium status over time
Time Frame: 2 weeks
|
Comparision of DelApp scores to DSM-5 criteria for delirium.
|
2 weeks
|
Inter-rater agreement of the DelApp
Time Frame: Baseline
|
Assessed by comparing researcher assessment scores to the scores of clinical staff who are delirium specialists.
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Elizabeth Wilson, Royal Infirmary of Edinburgh
- Principal Investigator: Jennifer Barnett, Cambridge Cognition Ltd
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DelApp
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Delirium
-
Efficacy Care R&D LtdHadassah Medical OrganizationUnknownDelirium | Delirium, Cause Unknown | Delirium of Mixed Origin | Delirium Confusional State | Delirium Drug-InducedIsrael
-
Imperial College Healthcare NHS TrustRecruitingCardiac Surgery | Intensive Care Unit Delirium | Post Operative DeliriumUnited Kingdom
-
Oslo University HospitalUniversity of Melbourne; Norwegian Academy of MusicRecruitingDelirium in Old Age | Delirium of Mixed Origin | Delirium Superimposed on Dementia | Delirium Confusional StateNorway
-
Menoufia UniversityCompleted
-
Universidad de SantanderUnknownDelirium of Mixed Origin | Hypoactive Delirium | Hyperactive DeliriumColombia
-
Johns Hopkins UniversityNational Institute on Aging (NIA)Active, not recruitingDelirium | Delirium on Emergence | Hearing Loss | Hearing Loss, High-Frequency | Hearing Loss, Sensorineural | Delirium, Cause Unknown | Hearing Loss, Bilateral | Hearing Disability | Delirium in Old Age | Delirium of Mixed Origin | Delirium Superimposed on Dementia | Delirium Confusional State | Delirium With... and other conditionsUnited States
-
Chinese PLA General HospitalBeijing Tiantan HospitalRecruiting
-
Charite University, Berlin, GermanyBARMERRecruitingDelirium in Old AgeGermany
-
Mayo ClinicCompletedPost-Operative DeliriumUnited States
-
University Hospital, Basel, SwitzerlandInnosuisse - Swiss Innovation AgencyRecruitingPostoperative Delirium (POD)Switzerland
Clinical Trials on No intervention given to participants
-
McMaster UniversitySt. Joseph's Healthcare HamiltonActive, not recruiting
-
Marmara UniversitySaglik Bilimleri UniversitesiCompletedOral Health in Children With Inflammatory Bowel DiseaseTurkey
-
Shenzhen Center for Disease Control and PreventionCompletedPuberty, Precocious
-
UConn HealthRecruitingMyocardial Infarction | Ischemia | Stroke, IschemicUnited States
-
University of Dublin, Trinity CollegeCompleted
-
University of LeicesterNot yet recruiting
-
Louisiana State University Health Sciences Center...University of South AlabamaCompletedSystemic Sclerosis | Pulmonary Hypertension | SclerodermaUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompletedPulmonary Hypertension | Acute Myocardial InfarctionChina
-
Renmin Hospital of Wuhan UniversityRecruitingHernia | Inflammatory Bowel Diseases | Gastric Cancer | Colorectal Cancer | Gastric Ulcer | HemorrhoidsChina